Skip to main content

Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study.

Publication ,  Journal Article
Cutler, AJ; Kollins, SH; Brams, MN; Corliss, M; Oh, C; Braeckman, R; Childress, AC
Published in: Front Psychiatry
2024

OBJECTIVE: To evaluate treatment responder rate using the Attention-Deficit/Hyperactivity Disorder Rating Scale-5 (ADHD-RS-5) score based on optimized dose level of serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) and changes in ADHD severity in children (aged 6-12 years) with ADHD. METHODS: During a 21-day dose-optimization phase, 155 patients initiated treatment with 39.2/7.8 mg SDX/d-MPH in the first week and then were titrated to an optimum dose; 5 patients were downtitrated to 26.1/5.2 mg, 76 were uptitrated to 52.3/10.4 mg, and 69 remained at 39.2/7.8 mg during the following 2 weeks. Responder threshold values were 30% and 50% based on the percent change from baseline (day 0) to days 7, 14, and 21 in the ADHD-RS-5 score. The Conners 3rd Edition-Parent score was used to assess weekly changes in ADHD severity during the dose-optimization and treatment phases. RESULTS: Of the 5 subjects whose dose was optimized at 26.1/5.2 mg, ≥80% across all days had ≥50% responder rate. Of the 69 subjects whose dose was optimized at 39.2/7.8 mg, 81.2% had ≥50% responder rate by day 21. Of the 76 subjects whose dose was optimized to 52.3/10.4 mg, 72.4% had ≥50% responder rate by day 21. Changes in ADHD severity, based on mean Conners 3rd Edition-Parent scores, improved from baseline at each visit during dose optimization for each subscale. At the dose-optimization phase, Conners 3rd Edition-Parent scores improved from baseline for SDX/d-MPH in all subscales. CONCLUSION: A high percentage of subjects were responders upon reaching their final optimized dose. SDX/d-MPH demonstrated significant reductions in ADHD severity in children based on the Conners 3rd Edition-Parent scores. Determining the optimal dosage of SDX/d-MPH and its effect on ADHD severity could enable the development of a more clinically relevant treatment regimen in children with ADHD.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Front Psychiatry

DOI

ISSN

1664-0640

Publication Date

2024

Volume

15

Start / End Page

1310483

Location

Switzerland

Related Subject Headings

  • 3202 Clinical sciences
  • 1701 Psychology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cutler, A. J., Kollins, S. H., Brams, M. N., Corliss, M., Oh, C., Braeckman, R., & Childress, A. C. (2024). Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study. Front Psychiatry, 15, 1310483. https://doi.org/10.3389/fpsyt.2024.1310483
Cutler, Andrew J., Scott H. Kollins, Matthew N. Brams, Meg Corliss, Charles Oh, Rene Braeckman, and Ann C. Childress. “Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study.Front Psychiatry 15 (2024): 1310483. https://doi.org/10.3389/fpsyt.2024.1310483.
Cutler AJ, Kollins SH, Brams MN, Corliss M, Oh C, Braeckman R, et al. Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study. Front Psychiatry. 2024;15:1310483.
Cutler, Andrew J., et al. “Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study.Front Psychiatry, vol. 15, 2024, p. 1310483. Pubmed, doi:10.3389/fpsyt.2024.1310483.
Cutler AJ, Kollins SH, Brams MN, Corliss M, Oh C, Braeckman R, Childress AC. Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study. Front Psychiatry. 2024;15:1310483.

Published In

Front Psychiatry

DOI

ISSN

1664-0640

Publication Date

2024

Volume

15

Start / End Page

1310483

Location

Switzerland

Related Subject Headings

  • 3202 Clinical sciences
  • 1701 Psychology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences